SCHEMBL3559611

SCHEMBL3559611

CC(C)(C)OC(=O)N(CCCNCc1cccs1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 5/20 0.44
NOS1 P29475 1/20 0.44
NOS2 P35228 1/20 0.44
GAA P10253 1/20 0.42
USP2 O75604 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
APOBEC3A P31941 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558567 0.86 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1NOS1NOS2GAA
SCHEMBL3610811 0.85 TDP1 (0.48) SMN1; SMN2HPGDL3MBTL1TP53ALDH1A1
SCHEMBL3563466 0.85 ALDH1A1 (0.46) SMN1; SMN2HPGDALDH1A1GAANPSR1
SCHEMBL3562561 0.85 ALDH1A1 (0.46) SMN1; SMN2HPGDNPC1RAB9AALDH1A1
SCHEMBL3565071 0.85 MMP9 (0.44) SMN1; SMN2ALDH1A1NOS1NOS2GAA
SCHEMBL3567756 0.84 MEN1 (0.56) SMN1; SMN2HPGDALDH1A1GAANPSR1
SCHEMBL3567257 0.84 ALDH1A1 (0.48) SMN1; SMN2HPGDALDH1A1GAANPSR1
SCHEMBL3563107 0.83 HTR5A (0.49) SMN1; SMN2HPGDALDH1A1NOS1NOS2
SCHEMBL3566727 0.83 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1GAANPSR1APOBEC3A
SCHEMBL3561765 0.81 ALDH1A1 (0.45) SMN1; SMN2HPGDNPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-20100094021-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES KALYPSYS, INC. (US) 2010-04-15 US disclosed
EP-1954695-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5-YL)-DIALKYL-AMINES Kalypsys, Inc. (US) 2008-08-13 EP disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2007062411-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5-YL)-DIALKYL-AMINES KALYPSYS, INC. (US) 2007-05-31 WO disclosed
US-20070123572-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES KALYPSYS, INC. (US) 2007-05-31 US disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094021-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES DCLK2, TH, DCLK3 SMN1; SMN2 3474/4885HPGD 2417/4885L3MBTL1 2967/4885
US-20070123572-A1 NOVEL METHOD OF PREPARATION OF 5-CHLORO-3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOLE AND (3-IMIDAZOL-1-YL-[1,2,4]THIADIAZOL-5YL)-DIALKYL-AMINES DCLK2, TH, DCLK3 SMN1; SMN2 3474/4885HPGD 2417/4885L3MBTL1 2967/4885
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 SMN1; SMN2 4446/4885HPGD 571/4885L3MBTL1 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.